Phibro Animal Health (PAHC) Liabilities and Shareholders Equity (2013 - 2026)
Phibro Animal Health (PAHC) posted quarterly Liabilities and Shareholders Equity of $1.4 billion for Q1 2026, up 9.71% year-over-year from $1.3 billion in Q1 2025, and up 2.81% quarter-over-quarter from $1.4 billion in Q4 2025.
Phibro Animal Health (PAHC) Liabilities and Shareholders Equity (2013 - 2026) Analysis & Trends
Phibro Animal Health's Liabilities and Shareholders Equity history runs 14 years deep, the most recent figure standing at $1.4 billion for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 9.71% year-over-year to $1.4 billion; the TTM figure through Mar 2026 stood at $5.6 billion (up 22.98% YoY), while the FY2025 annual figure was $1.4 billion, up 38.56% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $1.4 billion, up from $1.4 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $1.4 billion in Q1 2026, with the low at $916.2 million in Q1 2022.
- The 5-year median for Liabilities and Shareholders Equity is $972.7 million (2023), against an average of $1.1 billion.
- The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity grew 0.18% in 2024, then surged 43.39% in 2025.
- Phibro Animal Health's Liabilities and Shareholders Equity stood at $961.8 million in 2022, then gained by 1.13% to $972.7 million in 2023, then surged by 32.16% to $1.3 billion in 2024, then rose by 9.34% to $1.4 billion in 2025, then gained by 2.81% to $1.4 billion in 2026.
- Business Quant data shows PAHC's Liabilities and Shareholders Equity at $1.4 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.4 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 6.18 Bn |
| 10 | Phibro Animal Health | 1.42 Bn | 1.35 Bn | 125.68 Mn | 1.45 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.45 Bn |
| Dec 31, 2025 | 1.41 Bn |
| Sep 30, 2025 | 1.39 Bn |
| Jun 30, 2025 | 1.36 Bn |
| Mar 31, 2025 | 1.32 Bn |
| Dec 31, 2024 | 1.29 Bn |
| Sep 30, 2024 | 966.29 Mn |
| Jun 30, 2024 | 982.18 Mn |
| Mar 31, 2024 | 979.04 Mn |
| Dec 31, 2023 | 972.71 Mn |
| Sep 30, 2023 | 964.52 Mn |
| Jun 30, 2023 | 971.40 Mn |
| Mar 31, 2023 | 965.43 Mn |
| Dec 31, 2022 | 961.83 Mn |
| Sep 30, 2022 | 948.38 Mn |
| Jun 30, 2022 | 931.70 Mn |
| Mar 31, 2022 | 916.18 Mn |
| Dec 31, 2021 | 848.96 Mn |
| Sep 30, 2021 | 836.04 Mn |
| Jun 30, 2021 | 841.33 Mn |